Clinical trials: Sjogren's Syndrome
Primary Sjogren's Syndrome
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
The purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.
- Trial name
- NCT05673993
- Testing
- Telitacicept 80 mg, Telitacicept 160 mg
- Where
- 78 sites in China
- Volunteers
- 381 people
- Sponsor
- RemeGen Co., Ltd.
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Systemic Lupus Erythematosus, Systemic Sclerosis
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06379646
- Testing
- YTS109
- Where
- China
- Volunteers
- 6 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Sjogrens Syndrome
Nipocalimab in Moderate to Severe Sjogren's Disease
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
- Trial name
- DAFFODIL (NCT06741969)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 254 sites in United States, Argentina and 26 more
- Volunteers
- 655 people
- Sponsor
- Janssen Research & Development, LLC
Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensory Neuropathies
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage.
- Trial name
- SERENITY (NCT07760818)
- Testing
- efgartigimod PH20 SC
- Volunteers
- 75 people
- Sponsor
- argenx
Sjögren's Syndrome, Sjogren's Syndrome
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against…
- Trial name
- phaethuSA (NCT04572841)
- Testing
- SAR441344
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Primary Sjögren Syndrome
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.
- Trial name
- NCT04830644
- Testing
- Iguratimod
- Where
- 30 sites in China
- Volunteers
- 144 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Sjogren Syndrome
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
- Trial name
- NEPTUNUS-2 (NCT05349214)
- Testing
- VAY736
- Where
- 146 sites in United States, Argentina and 24 more
- Volunteers
- 506 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sjogren's Syndrome
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
- Trial name
- NCT04968912
- Testing
- Nipocalimab, Standard of Care Treatment
- Where
- 69 sites in United States, France and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Primary Sjogren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
- Trial name
- UPSTREAM SjD (NCT07404865)
- Testing
- Telitacicept
- Where
- 49 sites in United States, Georgia
- Volunteers
- 250 people
- Sponsor
- Vor Biopharma
Dry Eye Syndromes, Sjögren Syndrome
A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
The purpose of this study is to evaluate the effectiveness of fluorometholone combined with sodium hyaluronate eye drops in the treatment of Sjögren syndrome.
- Trial name
- NCT02011776
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Santen Pharmaceutical(China) Co.,LTD
Sjögren's Syndrome
MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome
This study is aSingle-center, multiple-dosing, prospective, nonrandom, single-arm trial.
- Trial name
- NCT07185139
- Testing
- MSCohi-O Lenses
- Volunteers
- 12 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Sjogren's Syndrome
Evaluation of FID 114657 in Sjogren's Syndrome Subjects
The primary objective of this study is to assess the overall Sjogren's Syndrome subject's preference for a particular product. Dry eye symptom relief will also be evaluated based on clinical evaluation and a set of subject…
- Trial name
- NCT01079871
- Testing
- FID 114657 (ORB Preserved Ocular Emulsion)
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Sjogren Syndrome
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
- Trial name
- NEPTUNUS-1 (NCT05350072)
- Testing
- VAY736
- Where
- 77 sites in United States, Austria and 16 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Xerostomia, Sjogren's Syndrome
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
The primary objective of this clinical study is to determine the impact of P-552 oral rinse on salivary volume after administration of a single dose of P-552and versus vehicle rinse.
- Trial name
- NCT01369589
- Testing
- P-552
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Parion Sciences
Dry Eye
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Primary objectives To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) >10mm/5min at Week 4 by testing the superiority.
- Trial name
- NCT05133180
- Testing
- Oxervate, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 104 people
- Sponsor
- Dompé Farmaceutici S.p.A
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb